AR and prostate carcinoma: Fig 4I shows that the combined treatment of enzalutamide and C3 has increased effects on growth inhibition of LNCaP cells, indicating the therapeutic potential of targeting both AR and Wnt/β-catenin pathways in prostate cancer.